125 related articles for article (PubMed ID: 17692320)
1. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes.
Laumen H; Skurk T; Hauner H
Atherosclerosis; 2008 Feb; 196(2):565-73. PubMed ID: 17692320
[TBL] [Abstract][Full Text] [Related]
2. Effects of rosuvastatin on fibrinolytic system of human umbilical vein endothelial cells in vitro.
He F; Zhao J; Guo R; Liang Y
Am J Med Sci; 2014 Oct; 348(4):319-23. PubMed ID: 24694789
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
Kang BY; Mehta JL
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):283-91. PubMed ID: 19724024
[TBL] [Abstract][Full Text] [Related]
4. Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity.
Swiatkowska M; Pawlowska Z; Szemraj J; Drzewoski J; Watala C; Cierniewski CS
Jpn J Pharmacol; 2002 Dec; 90(4):337-44. PubMed ID: 12501010
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh.
Choi EY; Chang W; Lim S; Song BW; Cha MJ; Kim HJ; Choi E; Jang Y; Chung N; Hwang KC
Eur J Pharmacol; 2010 Feb; 627(1-3):56-62. PubMed ID: 19883640
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells.
Lazzerini PE; Capperucci C; Spreafico A; Capecchi PL; Niccolini S; Ferrata P; Frediani B; Galeazzi M; Laghi-Pasini F
Joint Bone Spine; 2013 Mar; 80(2):195-200. PubMed ID: 22999910
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells.
Kim YS; Ahn Y; Hong MH; Kim KH; Park HW; Hong YJ; Kim JH; Kim W; Jeong MH; Cho JG; Park JC; Kang JC
J Cardiovasc Pharmacol; 2007 Jun; 49(6):376-83. PubMed ID: 17577102
[TBL] [Abstract][Full Text] [Related]
8. TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes.
Lobo SM; Quinto BM; Oyama L; Nakamichi R; Ribeiro AB; Zanella MT; Dalboni MA; Batista MC
Cytokine; 2012 Oct; 60(1):150-6. PubMed ID: 22658637
[TBL] [Abstract][Full Text] [Related]
9. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
Stalker TJ; Lefer AM; Scalia R
Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
[TBL] [Abstract][Full Text] [Related]
10. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
Landsberger M; Jantzen F; Könemann S; Felix SB
Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor.
Kiyan J; Kusch A; Tkachuk S; Krämer J; Haller H; Dietz R; Smith G; Dumler I
Atherosclerosis; 2007 Dec; 195(2):254-61. PubMed ID: 17275828
[TBL] [Abstract][Full Text] [Related]
12. Effects of HMG-CoA reductase inhibitor on experimental autoimmune myocarditis.
Liu X; Li B; Wang W; Zhang C; Zhang M; Zhang Y; Xia Y; Dong Z; Guo Y; An F
Cardiovasc Drugs Ther; 2012 Apr; 26(2):121-30. PubMed ID: 22382902
[TBL] [Abstract][Full Text] [Related]
13. Direct effects of rosuvastatin on pancreatic human beta cells.
Bugliani M; Syed F; Masini M; Marselli L; Suleiman M; Novelli M; Filipponi F; Boggi U; Masiello P; De Tata V; Marchetti P
Acta Diabetol; 2013 Dec; 50(6):983-5. PubMed ID: 23503985
[No Abstract] [Full Text] [Related]
14. Hydroxymethylglutaryl--CoA reductase inhibitor inhibits induction of nitric oxide synthase in 3T3--L1 preadipocytes.
Dobashi K; Araki S; Kubo K; Kawagoe R; Yamamoto Y; Shirahata A
Life Sci; 2008 Jan; 82(1-2):85-90. PubMed ID: 18036617
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents.
Capra V; Rovati GE
Pulm Pharmacol Ther; 2014 Feb; 27(1):10-6. PubMed ID: 23806820
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin inhibits pressure-induced fibrotic responses via the expression regulation of prostacyclin and prostaglandin E2 in rat renal tubular cells.
Chen CH; Cheng CY; Chen YC; Sue YM; Hsu YH; Tsai WL; Chen TH
Eur J Pharmacol; 2013 Jan; 700(1-3):65-73. PubMed ID: 23276663
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes.
Sakamoto K; Osaki M; Hozumi A; Goto H; Fukushima T; Baba H; Shindo H
BMC Musculoskelet Disord; 2011 Apr; 12(1):82. PubMed ID: 21524281
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung.
Chang CC; Wang SS; Hsieh HG; Lee WS; Chuang CL; Lin HC; Lee FY; Lee SD; Huang HC
Clin Sci (Lond); 2015 Sep; 129(6):449-60. PubMed ID: 25940601
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
Takeshita Y; Takamura T; Hamaguchi E; Shimizu A; Ota T; Sakurai M; Kaneko S
Metabolism; 2006 Nov; 55(11):1464-72. PubMed ID: 17046548
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes.
Pandey M; Loskutoff DJ; Samad F
FASEB J; 2005 Aug; 19(10):1317-9. PubMed ID: 15928193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
